Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2017 Dec 8;5(1):ofx267. doi: 10.1093/ofid/ofx267

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2017. Published by Oxford University Press on behalf of Infectious Diseases Society of America.

This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com

PMC Copyright notice

Figure 1. — Decision tree evaluating 8-week vs 12-week therapy for HCV. Figure 1 is a schematic of our model. All individuals begin the analysis ready for treatment. Following firstline therapy, individuals’ chance of attaining SVR is based on the efficacy of the firstline regimen. Among those failing to achieve SVR, they are either retained in care or lost to follow-up. Those lost to follow-up never achieve SVR. Those retained are treated with salvage therapy and attain SVR with a probability equal to the efficacy of the salvage therapy. At the end of each branch (SVR or no SVR), lifetime cost and QALY outcomes are calculated via the HEP-CE model. Abbreviations: HCV, hepatitis C virus; HEP-CE, Hepatitis C Cost-Effectiveness Model; QALY, quality-adjusted life-year; SVR, sustained virologic response.